Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Income from Non-Controlling Interests (2022 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Income from Non-Controlling Interests for 9 consecutive years, with -$2.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Non-Controlling Interests fell 20.44% year-over-year to -$2.6 million, compared with a TTM value of $31.3 million through Dec 2025, up 418.8%, and an annual FY2025 reading of $31.7 million, up 411.23% over the prior year.
  • Income from Non-Controlling Interests was -$2.6 million for Q4 2025 at Arrowhead Pharmaceuticals, down from $39.9 million in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $39.9 million in Q3 2025 and bottomed at -$3.4 million in Q2 2025.
  • Average Income from Non-Controlling Interests over 4 years is $1.0 million, with a median of -$1.9 million recorded in 2024.
  • The sharpest move saw Income from Non-Controlling Interests plummeted 416.87% in 2023, then surged 1519.91% in 2025.
  • Year by year, Income from Non-Controlling Interests stood at -$486000.0 in 2022, then tumbled by 416.87% to -$2.5 million in 2023, then increased by 15.09% to -$2.1 million in 2024, then decreased by 20.44% to -$2.6 million in 2025.
  • Business Quant data shows Income from Non-Controlling Interests for ARWR at -$2.6 million in Q4 2025, $39.9 million in Q3 2025, and -$3.4 million in Q2 2025.